Connotation of Traditional Chinese Medicine's Protection of Pulmonary Microvascular Endothelial Cells in Prevention and Treatment of Chronic Obstructive Pulmonary Disease Based on "Lung Collateral Theory"
10.13422/j.cnki.syfjx.20241536
- VernacularTitle:基于“肺络理论”探讨中医药保护肺微血管内皮细胞防治慢性阻塞性肺疾病的内涵
- Author:
Jingjing XIN
1
;
Tongxing WANG
2
;
Ningxin HAN
2
Author Information
1. Graduate School， Hebei Medical University， Shijiazhuang 050017， China
2. State Key Laboratory for Innovation and Transformation of Luobing Theory，Shijiazhuang 050035， China
- Publication Type:Journal Article
- Keywords:
chronic obstructive pulmonary disease;
lung collateral theory;
traditional Chinese medicine;
pulmonary microvascular endothelial cells
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(7):221-229
- CountryChina
- Language:Chinese
-
Abstract:
Chronic obstructive pulmonary disease （COPD） is a common disease with a high incidence and mortality rate in the world. It is characterized by chronic inflammation and structural obstruction and is not completely reversible which will lead to shortness of breath caused by air retention and physical exertion. Traditional Chinese medicine proposes the concept of "lung collaterals"， which refers to the collateral vessels scattered throughout the lungs and lung system. The lung collaterals include the pulse collaterals and Qi collaterals. The blood circulation in the pulse collaterals belongs to Yin， distributed internally along the way. The Qi circulation in the Qi collateral belongs to Yang and is distributed externally. In western medicine， the pulse collaterals have an identity with large， medium， and small blood vessels， microvessels， and especially microcirculation. The Qi collateral encompasses systems such as the nervous， endocrine， and immune system. Pulmonary microvascular endothelial cells （HPMECs） are an important component of the pulmonary microvascular endothelium. Recent studies have found that HPMECs are the main damaged cells in the pathogenesis of COPD， mediating the occurrence and development of COPD. Traditional Chinese medicine can regulate HPMECs to treat COPD through multiple components， targets， and pathways， and has the advantage of reducing western medicine resistance and many side effects. Based on the "lung collateral theory"， this paper focused on HPMECs， and elaborated on the new connotation of traditional Chinese medicine in protecting HPMECs to treat COPD， aiming to provide new insights for the clinical treatment of COPD by protecting HPMECs.
